💊 医薬品 A-Z 🧬 標的 🛠 ツール 📚 ガイド
全医薬品 薬物分類 治療領域 副作用
ガイド 用語集 年表
比較 薬物の体内の旅 薬物ファミリー
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Aripiprazole Lauroxil

CHEMBL2219425 Phase 4 承認済み Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
660.7 g/mol
LogP
10.0
Phase
4

A prodrug form of aripiprazole attached to a fatty acid chain, formulated as a long-acting injectable that is slowly converted to aripiprazole over weeks following a single injection. It provides extended release to improve medication adherence in schizophrenia.

分子量

660.7000 g/mol

LogP

10.00

TPSA

62.30 Ų

リピンスキーの五則

不適合

治療領域

Schizophrenia

作用機序

Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

機序

Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

2D構造

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CCCCCCCCCCCC(=O)OCN1C(=O)CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc21

                

                

                
                

                    
InChI

                    
InChI=1S/C36H51Cl2N3O4/c1-2-3-4-5-6-7-8-9-10-16-35(43)45-28-41-33-27-30(19-17-29(33)18-20-34(41)42)44-26-12-11-21-39-22-24-40(25-23-39)32-15-13-14-31(37)36(32)38/h13-15,17,19,27H,2-12,16,18,20-26,28H2,1H3

                

                

                

                    
                    

                        
Molecular Formula

                        
C36H51Cl2N3O4

                    

                    
                    

                        
HBD / HBA

                        
- / 6

                    

                    
                    

                        
回転可能結合数

                        
20

                    

                    
                    
                    

                        
重原子数

                        
45

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
よくある質問

                

                    
                    

                        
                        

                            
A prodrug form of aripiprazole attached to a fatty acid chain, formulated as a long-acting injectable that is slowly converted to aripiprazole over weeks following a single injection. It provides extended release to improve medication adherence in schizophrenia.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Aripiprazole Lauroxil is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL2219425.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 49831411.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
医学的免責事項

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.